Luteolin has been reported to exhibit the antioxidant activity in glucocorticoid-induced osteoporosis by regulating the ERK/Lrp-5/GSK-3β pathway in vivo and in vitro.[25] Notably, these active components synergistically exert antiinflammatory, maintenance of estrogen level and antioxidative stress bone formation, which can be regarded as potential therapeutic strategies on OP. Here, LRP5 is linked to osteoporosis.